Immunic, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 93.61 million compared to USD 120.41 million a year ago. Basic loss per share from continuing operations was USD 2.11 compared to USD 3.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.245 USD | -0.40% | -1.97% | -17.00% |
May. 08 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.00% | 112M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.53% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023